Company type
Limited Corporation
Established
1988
Size
Large
Employees
1000+
Revenue
5,220 MDKK
Gross profit
3,278 MDKK
Operating Profit (EBIT)
1,858 MDKK
Profit for the Year
1,462 MDKK
Equity
3,757 MDKK
ad

More financial key figures and analyses?

In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!

Rank Profit for the Year

Rank in industry
3/47
"Top 10%"
Rank in Denmark
111/303,147
"Top 10%"

Top management Top 3

Board Top 3

Søren Westh Lonning 6Chairman of board
Torsten Steenholt Christensen 4Vice chairman
Winnie Højvang Bügel 2Boardmember

Legal owners Top 3

100%Chr. Hansen Holding A/S

Rights certificate

Selskabet tegnes af bestyrelsens formand eller bestyrelsens næstformand i forening med en direktør eller et andet medlem af bestyrelsen, eller af den administrerende direktør i forening med en direktør, eller af den samlede bestyrelse.

Company information based on CVR

NameChr. Hansen A/S
Alternate namesBiopax A/S, Chl Bio Products A/S, Chl Bioindustries A/S, Chl Food Ingredients A/S, Chl International A/S, Chr. Hansen Biosystems A/S, Chr. Hansen'S A/S, Chr. Hansen'S Agro Systems A/S, Chr. Hansen'S Bio Farming A/S, Chr. Hansen'S Bio Systems A/S, Chr. Hansen'S Lab. Danmark A/S, Chr. Hansen'S Laboratorium Danmark A/S, G. C. Starup A/S, Gastronomisk Institut A/S, Gourmet Food Institute A/S, Gourmet Ingredients A/S, N. Kjærgaard-Jensen'S Tekn. Kem. Fabrik, Eftf. A/S, Richard Eilersen A/S, Chemical Works, Starter Corporation A/S, Chr. Hansen´s Laboratorium Danmark A/S Show more
CVR12516479
AddressBøge Alle 10-12, 2970 Hørsholm
IndustryManufacture of other chemical products n.e.c. [205900]
Established01-09-1988 (32 yr)
Company typeLimited Corporation
Number of employees1000+ (CVR)
Advertising protectionNo
AuditorPricewaterhousecoopers Statsautoriseret Revisionspartnerselskab since 01-07-2011
Financial statement period01-09 to 31-08
Company capital194,101,000 DKK
194,100,000 DKK (06-03-2000 - 26-01-2003)
183,500,000 DKK (24-04-1997 - 05-03-2000)
150,000,000 DKK (04-02-1994 - 23-04-1997)
100,000,000 DKK (20-07-1992 - 03-02-1994)
80,000,000 DKK (02-03-1989 - 19-07-1992)
Articles of assoc. last06-12-2017

Member of industries

Purpose

Selskabets formål er direkte at drive fabrikation af og handel med bioteknologiske og kemiske produkter, processer og anlæg, at drive forskning og yde rådgivning. Selskabet kan tillige foretage investeringer i virksomheder i ind- og udland, i fast ejendom samt drive finansieringsvirksomhed, når dette falder inden for formålet, og efter bestyrelsens nærmere bestemmelser anden virksomhed i øvrigt i forbindelse med formålet

Financial Statement

 201920182017
Currency/unit000' DKK000' DKK000' DKK
Revenue
5,219,517
-1%
5,254,185
-5%
5,530,908
+15%
Gross Profit
3,278,005
+13%
2,911,524
+2%
2,842,944
+19%
Profit for the Year
1,462,142
+10%
1,333,943
+0%
1,330,210
+17%
Equity
3,757,039
+14%
3,294,896
+11%
2,960,954
+13%
Total Assets
6,981,798
+11%
6,286,998
+7%
5,895,271
+14%

Mangement review

Management commentaryChr. Hansen A/S is a company within the Chr. Hansen Group, and it is 100% owned by Chr. Hansen Holding A/S.The financial year 2018/19 has been a satisfying year for Chr. Hansen A/S. A sustainable business model combined with an adaptable organization has secured Chr. Hansen yet another year with growth – both in the most important business areas and financially.Business structureChr. Hansen A/S is organized into two business units. The business units Food Cultures & Enzymes and Health & Nutrition.Food Cultures & EnzymesChr. Hansen is the market leader on the cultures and enzymes market. Our goal is to deliver innovative solutions of the highest quality on the culture and enzymes market. It is an important part of Chr. Hansen’s strategy to continuously enable our customers to improve their business with new concepts which create value in dairy products and processes and at the same time optimize food safety.Health & NutritionBesides the animal and feed industry, the division is developing new products for the food supplement industry and the pharmaceutical industry, first and foremost based on probiotic cultures. Chr. Hansen is one of the global leaders within the areas. The business area within microbiome has continued its development in the financial year 2017/18.Creative and committed employeesAs a knowledge-based company Chr. Hansen is very dependent on having committed and motivated employees, as well as skilled managers. Chr. Hansen therefore invests in the development of competences through ambitious development programs for employees and managers. Besides this competence based platform, we are ready to further develop our activities within our existing business areas.A sustainable businessIn the Chr. Hansen Group, we take our responsibility to do business in a sustainable way very seriously. We have constant focus on creating value while keeping our impact on the surrounding society to a minimum and securing a good working environment for all our employees.Building an inclusive culture for a diverse workforceAs a company driven by science and innovation, our future relies on our ability to generate ideas, create solutions, and approach problems in new ways. To achieve this, we need a workforce of employees with diverse socio-economic backgrounds, experiences and points of view. We strive to develop a diverse workforce and an engaged, innovative and open-minded culture, where each employee’s unique differences are not only acknowledged and encouraged, but where they add value and make our organization stronger.While we are proud of the diversity of our workforce today, we acknowledge that we still have more work to do, primarily in terms of improving our gender diversity and developing more varied skillsets among teams of employees. Recognizing that diversity challenges are unique to teams and locations, Chr. Hansen works on a range of parameters to help raise the bar, for example by focusing on unconscious bias and developing engaging and inspiring leaders.Diversity metrics are also included in the corporate leadership team’s remuneration, reflecting the degree to which it represents a strategic objective.Research and developmentFor the Chr. Hansen Group, innovation is an important contributor to business growth. More than 500 people, which exceeds 30% of the total number of employees, are working with research and development.The Chr. Hansen Group generally patents all new products of commercial value. The patents protect our investments in research and development and increase the value of our business. In addition, we make sure that our product technology and application methods are protected by a wide patent portfolio.Risk managementIn the Chr. Hansen Group, we view risk management as an integrated part of managing the business. We strive to make sure that we do business in a prudent way where we assess and manage both financial and non-financial risks to protect our employees, assets and reputation. At least once a year, the Board of Directors reviews the risk exposure associated with the activities of the Chr. Hansen Group. Guidelines are adopted for areas of risk, and the development is monitored to secure that identified risks are accounted for, including strategic, operational and financial risks.RiskRisks relate to future events or developments that may have an influence on the company achieving its targets. Relevant risks are identified, monitored and reported to the Executive Board and the Board of Directors through an Enterprise Risk Management process following an annual cycle. Furthermore, the identified risks are presented to and discussed by Management on a quarterly basis. The purpose of this process is to identify risks as early as possible and enable Management to proactively adapt business processes and controls to meet, manage or mitigate these risks.Identified risks are evaluated based on their possible safety, business or financial impact and the likelihood of the risk materializing. Clear roles and responsibilities are assigned for major risks, and mitigation initiatives are identified, prioritized and launched. The most significant risks identified and reported to the Board of Directors are described below, including measures taken to mitigate these.Chr. Hansen A/S continues to work on identifying and evaluating relevant risks, and the list does not include all risks that could ultimately affect the Company.Production riskChr. Hansen A/S has two main production sites in Denmark; these sites together with the group’s sites in Germany, France and US represent the core of Chr. Hansen’s business, and each site carefully monitors product safety and delivery performance to manage all potential risks. This consolidation of production allows capacity to be optimized in order to reduce production costs. To minimize the risk of production breakdowns or failures, Chr. Hansen has implemented a risk prevention program where regular audits are conducted, which ensures preventive maintenance and replacements. The company also maintains idle capacity for key processes. As production processes are optimized and automated, dependence on robust IT systems and infrastructure increases. Chr. Hansen continues to reduce complexity in IT systems and conduct regular restore tests.With this concentrated production setup, there is a risk of a production breakdown interrupting the company’s operations and leading to a loss of income in both the short term and the longer term due to long lead times on the replacement of key equipment.The causes might be contamination of production equipment, key equipment breakdown, fire, terrorism and natural disasters.The risk and effect of a production breakdown are mitigated through maintenance, insurance, fire safety measures, behavior-based training, continuous improvements to operational processes and business continuity plans including alternative production possibilities.Product safetyThe majority of Chr. Hansen's products are sold to the food & beverage, human health, animal health and plant protection industries. Most products are components in customers’ end products that are consumed as food, beverages or dietary supplements.To ensure the highest product safety, Chr. Hansen has an extensive quality assurance and food safety program covering the entire value chain, from the sourcing of raw materials until the finished products are delivered to customers. The risk assessment performed in the food safety program includes an evaluation of the use of our products in customers’ end products. Chr. Hansen’s food safety program is certified according to internationally recognized food safety standards. The Danish production sites are FSSC 22000 certified.Health, safety & securityChr. Hansen is committed to continuously improving both the physical and psychological working environment for its employees. The company has implemented several initiatives to underline the importance of a safe working environment. Monitoring and follow-up of incidents have been strengthened from departmental level to the Executive Board. There is also focus on behavior in relation to IT security due to the increased risk of cybercrime.Financial riskAs an international business, Chr. Hansen A/S is exposed to a number of financial risks relating to currency and interest rate fluctuations, funding, liquidity, credit and counterparty risks.Legal riskChr. Hansen A/S is from time to time a party to legal proceedings arising in the ordinary course of business. The legal department is focused on analyzing possible risks in a timely manner and mitigating them in an appropriate way using both internal and, if necessary, external capabilities. Despite the focus from Chr. Hansen on these matters, the outcome of legal proceedings cannot be predicted with certainty.ResultsChr. Hansen A/S achieved revenue in 2018/19 of DKK 5,220 million, equal to a decrease in revenue of 1%. The net revenue decrease is caused by a mix of the development in exchange rates and actual sales.In total, DKK 522 million, equal to a share of 10% of total revenue, was spent on research and development expenditure. DKK 84 million was capitalized in 2018/19 (DKK 79 million in 2017/18). Thereby, research and development spending has decreased by DKK 5 million compared with the previous financial year.Chr. Hansen A/S’s results before tax present a profit of DKK 1,860 million, against DKK 1,711 million in the previous financial year. The result after tax amounts to DKK 1,462 million in financial year 2018/19, compared to DKK 1,334 million in 2017/18.The number of employees amounts to 1,445 at the end of the financial year, compared to 1,278 for 2017/18.Management regards the results for the financial year as satisfactory and in accordance with expectations.InvestmentsThe investment activities amounted to DKK 1,117 million in 2018/19, compared to DKK 549 million in 2017/18. The high investment level in 2018/19 is reflected by the acquisition of Hündsbichler and the packaging plant for freeze dry in Avedøre, we refer to the Annual Report 2018/19 for Chr. Hansen Holding A/S.Capital structureOn August 31, 2019 equity amounts to DKK 3,757 million, equal to an equity ratio of 54%. A dividend of DKK 1,000 million has been paid out to the parent company.OutlookThe results for the financial year 2018/19 are a little below our expectations. Revenue and operating profit are expected to increase in the financial year 2019/20. Cash flows are expected to stay at the same level as in 2018/19.Events after the balance sheet dateAfter the balance sheet date until today’s date, no events have occurred, which could influence the evaluation of this annual report.
03-12-2019

Map